14 The abovementioned studies barely addressed children and adolescents, and Kelishadi et al.15 explored the relationship among VDD, insulin resistance, and related cardiometabolic disease risk factors such as blood glucose, blood pressure, blood lipids, and obesity in obese children with vitamin D supplementation. The authors concluded that vitamin D supplementation was beneficial to cardiometabolic disease control
in obese children and adolescents. This is the evidence regarding the correlation between VDD and cardiometabolic diseases in younger populations. However, there Rucaparib price are some caveats in the research by Kelishadi et al.15 Firstly, a control group of normal-weight children is necessary, since there was no data demonstrating that vitamin D levels in the obese children was lower than that of eutrophic children;
this was assumed by the authors based on a previous result.16 If there were no obvious differences of vitamin D levels between the subjects of the study and the eutrophic population, the rationale of vitamin D interference would be a concern. Secondly, to meet the statistical analysis requirement, the authors carefully designed the experiment to Selleckchem FK228 guarantee that there were at least 20 samples in each group, and that there was positive result in each group. However, the authors didn’t describe in detail the standards applied to decide which samples would be included, especially regarding the differentiation between
Leukotriene-A4 hydrolase simple obesity from secondary obesity that should be excluded. It’s unknown whether vitamin D supplementation would be effective in secondary obesity patients, in whom VDD is probable. It was unclear why the authors chose obese children and adolescents aged 10 to 16 years old, and it is quite possible that the data accuracy and conclusion validity might have be compromised due to the inconsistency of the baseline for different populations included in the study. To define cardiometabolic risk factors and metabolic syndrome, the authors applied the latest cut-off points provided by the National Heart, Lung, and Blood Institute for the pediatric age group and the continuous value of metabolic syndrome (cMetS) score, as recommended by the American Diabetes Association and by the European Association for the Study of Diabetes for children and adolescents, respectively. It is a concern whether these standards are appropriate for the study and whether they reflect the true situation of the population of interest. Analyzing previous research on VDD and cardiometabolic diseases, it’s natural to hypothesize that a small sample pool and improper sample selection are important reasons for the negative results obtained by the authors.